Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Cipla.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Cipla
india-flag Flag
Country
Country
India
Address
Address
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra 400 013
Telephone
Telephone
+91 22 23082891 / 23095521
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Under the amendment Cipla and Pulmatrix agreed to stop patient enrollment of the Ph2b study of PUR1900 (itraconazole) at 8 subjects and close the study. Cipla will take sole responsibility for development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis.


Lead Product(s): Itraconazole

Therapeutic Area: Infections and Infectious Diseases Product Name: PUR1900

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Pulmatrix

Deal Size: Undisclosed Upfront Cash: $22.0 million

Deal Type: Agreement January 08, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.


Lead Product(s): Glycine,Calcium

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nozohaem

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Actor Pharma

Deal Size: $48.6 million Upfront Cash: $48.6 million

Deal Type: Acquisition September 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.


Lead Product(s): Vildagliptin

Therapeutic Area: Endocrinology Product Name: Galvus

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.


Lead Product(s): ETH45

Therapeutic Area: Rare Diseases and Disorders Product Name: ETH45

Highest Development Status: DiscoveryProduct Type: Large molecule

Recipient: Ethris

Deal Size: $16.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.


Lead Product(s): Tamsulosin,Solifenacin Succinate

Therapeutic Area: Urology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection. . It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe.


Lead Product(s): Leuprolide Acetate

Therapeutic Area: Oncology Product Name: Leuprolide Acetate-Generic

Highest Development Status: ApprovedProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 29, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as; Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma.


Lead Product(s): Lenalidomide

Therapeutic Area: Oncology Product Name: Lenalidomide-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The ‘4-in-1’ combination contains an antiretroviral combination of Abacavir, as an alternative first-line regimen for infants and young children with HIV – in the form of granule-filled capsules.


Lead Product(s): Abacavir,Lamivudine,Lopinavir

Therapeutic Area: Infections and Infectious Diseases Product Name: ABC/3TC/LPV/r

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cipmolnu® (Molnupiravir 200mg), first oral antiviral approved by the UK MHRA for the treatment of mild-to-moderate COVID-19 receives EUA by permission by the Drug Controller General of India.


Lead Product(s): Molnupiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Cipmolnu

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 28, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Company received final approval for its Lanreotide acetate-Generic Injection, from USFDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.


Lead Product(s): Lanreotide Acetate

Therapeutic Area: Endocrinology Product Name: Lanreotide Acetate-Generic

Highest Development Status: ApprovedProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 19, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY